Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery
NCT07654296Phase 3Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, open-label trial of suzetrigine in postoperative pain (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Post-discharge opioid consumption (MME). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
suzetrigine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07654296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654296.